2023-08-18 18:32
Cornea Damage Cell Therapy Shows Promise in Phase I Trial
BOSTON– A team led by researchers from Mass Eye and Ear, a member of Mass General Brigham, reports the results of a phase I trial of a revolutionary stem cell treatment called cultivated autologous limbal epithelial cell transplantation (CALEC), which was found to be safe and well-tolerated over the short term in four patients with significant chemical burns in one eye. According to the study published August 18 in Science Advances, the patients who were followed for 12 months experienced restored cornea surfaces — two were able to undergo a corneal transplant and two reported significant improvements in vision without additional treatment.

https://www.miragenews.com/cornea-damage-cell-therapy-shows-promise-in-1068318/

#miragenews